Benzyl derivative compounds having peroxisome proliferator-activated receptor α (PPARα) agonistic activity, kits and compositions containing such compounds, and methods of their use in enhancing PPARα activity for treating diseases and/or conditions involving inflammation and/or angiogenesis, particularly ocular diseases and/or conditions such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema.

Compositions and methods for isolating L-glufosinate from a composition comprising L-glufosinate and glutamate are provided. The method comprises converting the glutamate to pyroglutamate followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The composition comprising L-glufosinate and glutamate is subjected to an elevated temperature for a sufficient time to allow for the conversion of glutamate to pyroglutamate, followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The glutamate alternatively may be converted to pyroglutamate by enzymatic conversion. The purified L-glufosinate is present in a final composition at a concentration of 90% or greater of the sum of L-glufosinate, glutamate, and pyroglutamate. In some embodiments, a portion of the glutamate in the starting composition may be separated from the L-glufosinate using a crystallization step. Solid forms of L-glufosinate materials, including crystalline L-glufosinate ammonium, are also described.

The invention relates to an organic phosphorous compound flame retardant, their preparation methods and applications. The organic phosphorous compound flame retardants are prepared by drop-wise adding at least one from the soluble salts of di-alkyl hypophosphorous acid or soluble salts of mono-alkyl hypophosphorous acid as well as at least one from the soluble salts of alkyl phosphorous acid or soluble salts of phosphorous acid into the solution of soluble non-halogen salt of II-IV valent metal to react, or drop-wise adding at least one from the di-alkyl hypophosphorous acid or mono-alkyl hypophosphorous acid, and at least one from the alkyl phosphorous acid or phosphorous acid into at least one from the active oxides or hydroxides of II-IV valent metal to react.

Provided are a method for preparing L-glufosinate and the intermediate compounds of formula (V) and formula (III).

This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

Provided are: a water-soluble composition which has excellent storage stability and is adaptable to a wide range of light sources and capable of forming a highly fine pattern; a method of producing a cured product of the same; a cured product of the same; and an acylphosphinate. The water-soluble composition contains: an acylphosphinate (A) represented by Formula (I) below, wherein X.sup.1 represents an aryl group having 6 to 15 carbon atoms; X.sup.2 represents a linear alkyl group having 1 to 8 carbon atoms or the like; A.sup.m+ represents an alkali metal ion or the like; and m represents a number of 1 to 3; and a compound (B) having a group represented by Formula (II) below, wherein R.sup.1 represents a hydrogen atom or the like; Z.sup.1 represents an oxygen atom or the like; R.sup.2 represents a hydrogen atom or the like; Z.sup.2 represents an alkylene group having 1 to 6 carbon atoms; n represents a number of 0 to 30; * means a bond; and, when the compound (B) has plural groups represented by Formula (II), plural R.sup.1′s, Z.sup.1′s, Z.sup.2′s and n's are each optionally the same or different. ##STR00001##

Provided are a method for preparing L-glufosinate and the intermediate compounds of formula (V) and formula (III).

The present disclosure relates to a novel crystalline form of L-glufosinate ammonium salt and a process for preparation thereof. The present disclosure also provides compositions comprising said form and a method for the control of undesired plant growth using said compositions.

A preparation method for glufosinate or a salt thereof, an enantiomer thereof, or mixtures of the enantiomer thereof in all ratios, comprising reacting a compound of formula (II) or a salt, an enantiomer, or mixtures of the enantiomer in all ratios with one or more compounds of formula (III) or mixtures thereof. ##STR00001##

A preparation method for glufosinate or a salt thereof, an enantiomer thereof, or mixtures of the enantiomer thereof in all ratios, comprising reacting a compound of formula (II) or a salt, an enantiomer, or mixtures of the enantiomer in all ratios with one or more compounds of formula (III) or mixtures thereof. ##STR00001##